LONG-TERM EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TUMOR NECROSIS FACTOR THERAPY: RESULTS OF THE RANDOMIZED, PHASE 3 SIRROUND-T STUDY

被引：0
|
作者：
Tanaka, Y. [1 ]
Aletaha, D. [2 ]
Agarwal, P. [3 ]
Kurrasch, R. [4 ]
Tak, P. P. [5 ]
Popik, S. [3 ]
机构：
[1] Univ Occupat & Environm Hlth, Dept Internal Med, Kitakyushu, Fukuoka, Japan
[2] Med Univ Vienna, Div Rheumatol, Vienna, Austria
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Stevenage, Herts, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.6486
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0214
引用
收藏
页码：563 / 564
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T)
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Harigai, Masayoshi
    Yamanaka, Hisashi
    Nakano, Toshikazu
    Akagi, Koshiro
    Ukyo, Yoshifumi
    Hsu, Benjamin
    MODERN RHEUMATOLOGY, 2019, 29 (02) : 306 - 313
  • [2] EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED GLOBAL PHASE 3 STUDY (SIRROUND-T)
    Pile, K.
    Aletaha, D.
    Tanaka, Y.
    Agarwal, P.
    Kurrasch, R.
    Tak, P.
    Popik, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 27 - 27
  • [3] WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY
    Tanaka, Y.
    Aletaha, D.
    Peterson, S.
    Ganguly, R.
    Kurrasch, R.
    Popik, S.
    Agarwal, P.
    Li, N.
    VALUE IN HEALTH, 2017, 20 (05) : A149 - A149
  • [4] Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
    Aletaha, Daniel
    Bingham, Clifton O., III
    Tanaka, Yoshiya
    Agarwal, Prasheen
    Kurrasch, Regina
    Tak, Paul P.
    Popik, Sharon
    LANCET, 2017, 389 (10075): : 1206 - 1217
  • [5] FINAL 5-YEAR SAFETY AND EFFICACY RESULTS OF A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS ANTI-TUMOR NECROSIS FACTOR THERAPY
    Smolen, Josef S.
    Kay, Jonathan
    Landewe, Robert
    Matteson, Eric K.
    Gaylis, Norman
    Wollenhaupt, J.
    Murphy, Frederick T.
    Han, Chenglong
    Gathany, Tim
    Xu, Stephen
    Zhou, Yiying
    Hsia, Elizabeth C.
    Doyle, Mittie K.
    RHEUMATOLOGY, 2014, 53 : 87 - 88
  • [6] Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
    Smolen, Josef S.
    Kay, Jonathan
    Landewe, Robert
    Matteson, Eric L.
    Gaylis, Norman B.
    Wollenhaupt, Juergen
    Murphy, Frederick T.
    Han, Chenglong
    Gathany, Timothy A.
    Xu, Stephen
    Zhou, Yiying
    Hsia, Elizabeth C.
    Doyle, Mittie K.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S991 - S991
  • [7] Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)
    Aletaha, Daniel
    Bingham, Clifton O.
    Karpouzas, George Athanasios
    Takeuchi, Tsutomu
    Thorne, Carter
    Bili, Androniki
    Agarwal, Prasheen
    Hsu, Benjamin
    Rao, Ravi
    Brown, Kurt
    Tanaka, Yoshiya
    RMD OPEN, 2021, 7 (01):
  • [8] FIVE-YEAR SAFETY AND EFFICACY OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS ANTI-TUMOR NECROSIS FACTOR THERAPY: FINAL STUDY RESULTS OF THE PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED GO-AFTER TRIAL
    Smolen, J. S.
    Kay, J.
    Landewe, R.
    Matteson, E. L.
    Gaylis, N.
    Wollenhaupt, J.
    Murphy, F. T.
    Han, C.
    Gathany, T.
    Xu, S.
    Zhou, Y.
    Hsia, C.
    Doyle, M. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 232 - 232
  • [9] SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, LEADS TO IMPROVEMENTS IN WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY
    Tanaka, Y.
    Aletaha, D.
    Peterson, S.
    Ganguly, R.
    Kurrasch, R.
    Popik, S.
    Agarwal, P.
    Li, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 580 - 580
  • [10] Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis
    Marcora, Samuele M.
    Chester, Kathryn R.
    Mittal, Gayatri
    Lemmey, Andrew B.
    Maddison, Peter J.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 84 (06): : 1463 - 1472
12345